维奈克拉联合地西他滨与强化化疗作为年轻初诊急性髓系白血病诱导治疗的比较
这项随机试验纳入188例适合强化化疗的18至59岁初诊急性髓系白血病患者,1:1随机接受维奈克拉联合地西他滨(VEN-DEC)或IA-12方案诱导。在意向治疗人群中,VEN-DEC组复合完全缓解率为89%,IA-12组为79%,非劣效性P=0.0021;VEN-DEC组≥3级感染更少,严重血小板减少持续时间更短。
要点
- VEN-DEC组复合完全缓解率89%(84/94)vs IA-12组79%(74/94),非劣效性P=0.0021
- VEN-DEC组≥3级感染32% vs IA-12组67%,严重血小板减少中位持续13天 vs 19天(P<.001)
- 中位随访12.1个月时,两组总生存和无进展生存相似
核心结论
- 在年轻初诊急性髓系白血病患者中,VEN-DEC诱导治疗的缓解率非劣效于IA-12,且安全性更优。
研究设计与样本
- 随机试验,纳入18至59岁适合强化化疗的初诊急性髓系白血病患者,1:1随机接受VEN-DEC或IA-12诱导。
- 共筛查255例,入组188例,每组94例;所有达到复合完全缓解的患者接受大剂量阿糖胞苷巩固治疗。
- 主要终点为诱导后复合完全缓解率;试验注册号NCT05177731。
主要发现
- 意向治疗人群中,复合完全缓解率VEN-DEC组89%(84/94)vs IA-12组79%(74/94),非劣效性P=0.0021。
- 可测量残留病灶阴性率VEN-DEC组80%(67/84)vs IA-12组76%(56/74)。
- 年龄≥40岁患者中复合完全缓解率VEN-DEC组91% vs IA-12组75%;不良风险患者中91% vs 42%;表观遗传突变患者中91% vs 67%。
- RUNX1::RUNX1T1融合患者中复合完全缓解率VEN-DEC组44% vs IA-12组88%。
- ≥3级感染VEN-DEC组32% vs IA-12组67%;严重血小板减少中位持续时间VEN-DEC组13天 vs IA-12组19天(P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venetoclax (VEN) combined with hypomethylating agents is approved for frontline therapy in older/unfit patients with acute myeloid leukemia (AML). However, prospective data on this low-intensity therapy in treatment-naive younger patients with AML are lacking. This study investigated the efficacy and safety of VEN plus decitabine (VEN-DEC) as induction in untreated young fit patients with AML in a randomized trial. Patients aged 18 to 59 years eligible for intensive chemotherapy were randomized 1:1 to receive VEN-DEC or IA-12 (idarubicin and cytarabine). All patients achieved composite complete remission (CRc) underwent high-dose cytarabine consolidation. The primary end point was CRc rate after induction. Of 255 screened, 188 were enrolled and randomly assigned, with 94 in each group. In the intention-to-treat population, CRc was 89% (84/94) in the VEN-DEC group vs 79% (74/94) in the IA-12 group (noninferiority P = .0021), with measurable residual disease negativity rates of 80% (67/84) vs 76% (56/74), respectively. VEN-DEC showed superior CRc in patients aged ≥40 years (91% vs 75%) and those with adverse risk (91% vs 42%) or epigenetic mutations (91% vs 67%), but lower CRc in RUNX1::RUNX1T1 fusion cases (44% vs 88%) than IA-12. Patients in the VEN-DEC group experienced fewer grade ≥3 infections (32% vs 67%) and shorter severe thrombocytopenia duration (median, 13 vs 19 days; P < .001). At a median follow-up of 12.1 months, overall and progression-free survival were similar between groups. In conclusion, VEN-DEC demonstrated noninferior response rates with superior safety over IA-12 in young patients with AML. The trial was registered at www.clinicaltrials.gov as #NCT05177731.
引用
- Lu J, Xue SL, Wang Y, et al. Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML. Blood. 2025. PMID: 40009498. doi:10.1182/blood.2024027217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。